One study showed that glycine-β-muricholic acid (Gly-MCA) ameliorates NASH in mice by inhibiting intestinal FXR and reducing the production of ceramides [70]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.